Abstract
Following the publication of this paper, the authors alerted the Editorial Office to the fact that a reader had informed them that miR‑152 overexpression did not affect cell apoptosis and cell cycle. The authors subsequently confirmed that they were unable to obtain consistent results from these experiments.Furthermore, an independent investigation of this paper revealed that the cell apoptotic data shown in Fig.2D were strikingly similar to those that had appeared in an article published previously with different authors, although one of the institutions was held in common. The authors have requested that the above article be retracted from the publication, and the Editor agrees with this course of action. The Editor apologizes to the readership for any inconvenience caused. [the original article was published in International Journal of Molecular Medicine 42: 643‑650, 2018; DOI: 10.3892/ijmm.2018.3636].
Highlights
Following the publication of this paper, the authors alerted the Editorial Office to the fact that a reader had informed them that miR‐152 overexpression did not affect cell apoptosis and cell cycle
An independent investigation of this paper revealed that the cell apoptotic data shown in Fig. 2D were strikingly similar to those that had appeared in an article published previously with different authors, one of the institutions was held in common
The Editor apologizes to the readership for any inconvenience caused
Summary
MiR‐152 inhibits rheumatoid arthritis synovial fibroblast proliferation and induces apoptosis by targeting ADAM10
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
